Alimera Sciences, Inc.

Deal signed for new treatment for diabetic macular edema

Published in Managed Care Business Week, March 15th, 2005

Alimera Sciences, Inc., an ophthalmic pharmaceutical company, and Control Delivery Systems, Inc., (CDS), a company that develops drug delivery systems for the eye, announced a worldwide agreement to codevelop and market a new pharmacologic treatment indicated for diabetic macular edema (DME), a major cause of vision loss in people suffering from diabetic retinopathy.

Alimera Sciences also has the option to develop three additional products using CDS' drug delivery technology.

"The prospect of offering patients with diabetes, their caregivers and ophthalmology professionals the convenience of an outpatient injection with the potential for 3-year drug...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Managed Care Business Week

Source: Managed Care Business Week (2005-03-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry